RxDoctor Payments Data

Thurein Kyaw, MD

Nephrology · Lynchburg, VANPI 1922356336

Payments from drug & device makers

$4,180in general payments, 2019–2025

Across 43 payments — averaging $97.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Medical Corporation$800
  • Vertex$787
  • BD$406
  • AstraZeneca$339
  • Bayer$285
  • Calliditas Therapeutics US Inc.$226
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$1,58738%
  • Speaking & faculty fees$40610%
  • Food & beverage$2,12351%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,180 in reported general payments places this provider in the 70th percentile of 298 nephrology providers in Virginia.

See all nephrology providers in Virginia

Medicare billing

Part B allowed, 2024
$231,565
Medicare patients
532
Services billed
2,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol64$64,124
XphozahTenapanor Hcl17$55,295
LokelmaSodium Zirconium Cyclosilicate18$18,202
Sevelamer Carbonate46$6,383
ProsolParenteral Amino Acid 20% No.116$4,688
SpsSodium Polystyrene Sulfon/Sorb15$3,836
Chlorthalidone183$2,787
Torsemide104$2,434
Calcitriol180$2,051
Calcium Acetate34$2,000
Midodrine Hcl22$1,345
Valsartan55$1,168
Losartan Potassium173$1,105
Tamsulosin Hcl107$1,005
Famotidine62$856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$339$82,32682 claims
ANI Pharmaceuticals, Inc.Valsartan$30$1,16855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 298 nephrology providers in Virginia.

Other nephrology in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →